Wave Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 4.95 Cr
as on 16-11-2024
- Company Age 27 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 5.07 M
as on 16-11-2024
- Revenue 49.70%
(FY 2023)
- Profit -2.13%
(FY 2023)
- Ebitda 21.41%
(FY 2023)
- Net Worth 6.29%
(FY 2023)
- Total Assets 59.21%
(FY 2023)
About Wave Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 4.95 Cr.
The company has closed loans amounting to ₹5.07 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Sanjay Gupta, Sarita Gupta, and Nikhil Gupta serve as directors at the Company.
- CIN/LLPIN
U24231DL1997PLC088998
- Company No.
088998
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
08 Aug 1997
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Wave Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Gupta  | Director | 28-Jan-2017 | Current |
| Sarita Gupta | Director | 10-Feb-2018 | Current |
| Nikhil Gupta | Director | 28-Jan-2017 | Current |
Financial Performance and Corporate Structure Insights of Wave Pharmaceuticals.
Wave Pharmaceuticals Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 49.7% increase. The company also saw a slight decrease in profitability, with a 2.13% decrease in profit. The company's net worth moved up by a moderate rise of 6.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Wave Pharmaceuticals?
In 2022, Wave Pharmaceuticals had a promoter holding of 95.70% and a public holding of 4.31%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Iwave Pharmaceuticals Private LimitedActive 5 years 1 monthSanjay Gupta and Sarita Gupta are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 07 Mar 2003 | ₹2.50 M | Satisfied |
Punjab National Bank Creation Date: 12 Dec 2001 | ₹2.57 M | Satisfied |
How Many Employees Work at Wave Pharmaceuticals?
Unlock and access historical data on people associated with Wave Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Wave Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Wave Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
